findmyKOL

Wissam Chatila, MD

Basic profile

Temple University

ORCIDNPI
RegionPhiladelphia, PA · NortheastSpecialtyPulmonary DiseaseFocusRespiratory
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH funding2008–2012

Wissam Chatila is a Respiratory physician affiliated with Temple University. OpenAlex indexes 69 publications with 2,012 citations (h-index 23).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
69publications

Distinct works indexed by OpenAlex, matched via ORCID.

2,012citations

Total citations across indexed works.

23h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
9companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2008–2012

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

3401 N Broad St
7th Flr Parkinson Pavilion
Philadelphia, PA 191405103

Telephone

215-707-5864

Registry record last updated 12 May 2016.

View the NPPES registry record

Industry payments

9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Respiratory

    75.6%
    Corticosteroid42.6%
    Trelegy Ellipta51%Breo Ellipta20%Fluticasone Propionate12%Budesonide-Formoterol Fumarate8%Breztri Aerosphere5%Symbicort5%
    Part D<11 patients
    beta2-Adrenergic Agonist15.1%
    Albuterol Sulfate Hfa100%
    Part D28 patients

    + 4 more classes in this area

  • Nervous system

    11.2%
    Benzodiazepine4.6%
    Alprazolam100%
    Part D<11 patients
    Cholinergic Receptor Agonist3.9%
    Varenicline Tartrate100%
    Part D<11 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    4.8%
    Corticosteroid4.8%
    Prednisone100%
    Part D18 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 20082012 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”